Biological treatment, mainly with anti-tumour necrosis factor (TNF)α agents, of patients with rheumatoid arthritis, has been shown to modify their clinical course and progression, and delay or avoid its radiological progression.^1,2 Disease remission in rheumatoid arthritis has been traditionally considered when there is no clinical or biochemical evidence of disease activity.³

Magnetic resonance imaging (MRI) has been shown to be more sensitive than clinical and radiological parameters in evaluating the bone erosions and the inflammatory phenomenon that …